Ubidecarenone
Ubidecarenone is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| allevia | unapproved drug other | 2025-02-27 |
| avalon organics coq10 repair wrinkle defense broad spectrum spf15 | OTC monograph final | 2012-10-31 |
| mecell rose coenzyme q10 serum mask pack | OTC monograph final | 2014-12-28 |
| virexa | unapproved drug other | 2025-09-05 |
| yves conopeptide luxury tighten creme eye mask | unapproved drug other | 2025-06-10 |
| zyrexal | unapproved drug other | 2020-02-10 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
293 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | 1 | 1 | 2 | 7 | 12 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | 3 | 1 | 2 | 3 | 9 |
| Male infertility | D007248 | EFO_0004248 | N46 | — | 1 | — | 1 | 7 | 9 |
| Infertility | D007246 | EFO_0000545 | — | 1 | 2 | — | 2 | 4 | 9 |
| Inflammation | D007249 | MP_0001845 | — | — | 3 | 2 | 2 | 3 | 8 |
| Hypercholesterolemia | D006937 | — | — | — | 1 | — | 3 | 4 | 8 |
| Oxidative stress | D018384 | EFO_1001905 | — | 1 | 2 | 1 | 1 | 2 | 6 |
| Myalgia | D063806 | — | M79.1 | — | 1 | 1 | 3 | 2 | 6 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | 1 | 2 | 1 | 5 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 1 | 2 | 1 | 4 |
Show 31 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 1 | 5 | 2 | — | 7 | 13 |
| Healthy volunteers/patients | — | — | — | 3 | 1 | 1 | — | 4 | 9 |
| Fatigue | D005221 | — | R53.83 | 1 | 2 | 2 | — | 4 | 8 |
| Mitochondrial diseases | D028361 | EFO_0000591 | — | — | 2 | 3 | — | 3 | 8 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 5 | 4 | — | — | 7 |
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | — | 2 | 2 | — | 3 | 6 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 2 | 1 | — | 4 | 6 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | 1 | — | 1 | 5 |
| Coronary artery disease | D003324 | — | I25.1 | — | 4 | 4 | — | — | 5 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | 2 | 1 | — | 2 | 5 |
Show 55 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic retinopathy | D003930 | EFO_0003770 | — | 1 | 2 | — | — | 2 | 5 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | — | — | 4 | 5 |
| Dry eye syndromes | D015352 | — | H04.12 | — | 1 | — | — | 3 | 4 |
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | 1 | 1 | — | — | 2 | 4 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | 1 | — | — | 3 | 4 |
| Colorectal neoplasms | D015179 | — | — | 1 | 1 | — | — | 1 | 3 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | 1 | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 2 | — | — | — | 3 |
| Sclerosis | D012598 | — | — | 1 | 2 | — | — | — | 3 |
| Heart arrest | D006323 | EFO_0009492 | I46 | — | 3 | — | — | — | 3 |
Show 47 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glaucoma | D005901 | EFO_0000516 | H40 | 1 | — | — | — | 4 | 5 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | 1 | — | — | — | 3 | 4 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | 2 | 3 |
| Aging | D000375 | GO_0007568 | R41.81 | 1 | — | — | — | 2 | 3 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 1 | — | — | — | 2 | 3 |
| Hypoxia | D000860 | — | R09.02 | 2 | — | — | — | — | 2 |
| Brain diseases | D001927 | — | G93.40 | 1 | — | — | — | 1 | 2 |
| Oligospermia | D009845 | — | N46.1 | 1 | — | — | — | 1 | 2 |
| Gliosarcoma | D018316 | — | — | 1 | — | — | — | — | 1 |
| Astrocytoma | D001254 | EFO_0000271 | — | 1 | — | — | — | — | 1 |
Show 18 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 5 | 5 |
| Periodontal diseases | D010510 | — | K05.6 | — | — | — | — | 4 | 4 |
| Keratoconjunctivitis sicca | D007638 | EFO_1000906 | — | — | — | — | — | 2 | 2 |
| Vomiting | D014839 | — | R11.1 | — | — | — | — | 2 | 2 |
| Aneuploidy | D000782 | — | — | — | — | — | — | 2 | 2 |
| Muscular diseases | D009135 | EFO_0002970 | G72.9 | — | — | — | — | 2 | 2 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | — | 2 | 2 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 2 | 2 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | — | — | — | 1 | 1 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | — | — | — | 1 | 1 |
Show 75 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ubidecarenone |
| INN | ubidecarenone |
| Description | Coenzyme Q10 is a ubiquinone having a side chain of 10 isoprenoid units. In the naturally occurring isomer, all isoprenyl double bonds are in the E- configuration. It has a role as a human metabolite, a ferroptosis inhibitor and an antioxidant. |
| Classification | Small molecule |
| Drug class | aldosterone antagonists (spironolactone type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC1=C(OC)C(=O)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C)=C(C)C1=O |
Identifiers
| PDB | — |
| CAS-ID | 303-98-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL454801 |
| ChEBI ID | 46245 |
| PubChem CID | 5281915 |
| DrugBank | — |
| UNII ID | EJ27X76M46 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 53,577 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
709 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use